Krystal Biotech (KRYS) EBITDA Margin (2023 - 2026)
Krystal Biotech (KRYS) posted quarterly EBITDA Margin of 49.0% for Q2 2026, up 798.0% year-over-year from 5.46% in Q2 2025, and up 6.23% on a QoQ basis from 46.12% in Q1 2026.
Krystal Biotech (KRYS) EBITDA Margin (2023 - 2026) Analysis & Trends
Krystal Biotech has reported EBITDA Margin for 4 years, with the latest figure at 49.0% in Q2 2026.
- EBITDA Margin for Q2 2026 came in at 49.0%, up 798.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 44.89% (up 605.0% YoY), and the FY2025 annual result was 41.45%, up 1882.0% from the prior year.
- EBITDA Margin grew to 49.0% in Q2 2026, from 46.12% in the prior quarter.
- Over five years, EBITDA Margin peaked at 49.0% in Q2 2026 and troughed at 303.8% in Q3 2023.
- A 4-year average of 2.87% and a median of 41.06% in 2025 frame the typical range for EBITDA Margin.
- The widest annual swing landed in 2024, when EBITDA Margin surged 33060 bps; it then sank 408 bps in 2025.
- A 4-year view of EBITDA Margin shows it stood at 7.71% in 2023, then jumped by 489 bps to 45.41% in 2024, then retreated by 9 bps to 41.33% in 2025, then advanced by 19 bps to 49.0% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 49.0% in Q2 2026, 46.12% in Q1 2026, and 41.33% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 49.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.00% |
| Mar 31, 2026 | 46.12% |
| Dec 31, 2025 | 41.33% |
| Sep 30, 2025 | 42.30% |
| Jun 30, 2025 | 40.93% |
| Mar 31, 2025 | 41.11% |
| Dec 31, 2024 | 45.40% |
| Sep 30, 2024 | 26.80% |
| Jun 30, 2024 | 12.18% |
| Mar 31, 2024 | -14.77% |
| Dec 31, 2023 | 7.71% |
| Sep 30, 2023 | -303.80% |